drugset
drugset / Trial / NCT05481476

Surufatinib Combined With Sintilimab and AG in First-line Therapy of Patients With Locally Advanced or Metastatic Pancreatic Cancer

NCT05481476 ↗

Phase 2 Active not recruiting 32 enrolled Sun Yat-sen University
NaSingle-groupOpen-labelTreatment

Summary

This is a single-center, single-arm, open-label, phase 2 clinical study, to explore the efficacy and safety of surufatinib combined with sintilimab and AG in first-line therapy of patients with locally advanced or metastatic pancreatic cancer.

Timeline

Start
2022-12-12
Primary completion
2025-12-31
Completion
2026-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Gemcitabine Small molecule 1000 mg/m2 Intravenous
Subject Paclitaxel Small molecule 125 mg/m2 Intravenous
Subject Sintilimab Monoclonal antibody 200 mg Intravenous
Subject Surufatinib Small molecule 250 mg Oral

Indications

malignant pancreatic neoplasm